Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1085-1091

  Møller, Michael B ^a   Gerdes, Anne Marie ^a   Skjødt, Karsten ^a   Mortensen, Leif S ^b   Pedersen, Niels T ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Danish Comp Ctr for Res and Educ   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CONTROLLED STUDY; GENE MUTATION; HIGH RISK POPULATION; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; T CELL LYMPHOMA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; APOPTOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DENMARK; DNA, NEOPLASM; EXONS; FEMALE; GENES, P53; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032901751     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Ries, L. A. G., Kosary, C. L., Hankey, B. F., Miller, B. A., and Edwards, B. K. SEER Cancer Statistics Review, 1973-1995. Bethesda, MD: National Cancer Institute, 1998.
2. Shipp, M. A., Harrington, D. P., Andersen, J. R., Armitage, J. O., Bonadonna, G., Brittinger, G., Cabanillas, F., Canellos, G. P., Coiffier, B., Connors, J. M., Cowan, R. A., Crowther, D., Dahlberg, S., Engelhard, M., Fisher, R. I., Gisselbrecht, C., Horning, S. J., Lepage, E., Lister, T. A., Meerwald, J. H., Montserrat, E., Nissen, N. I., Oken, M. M., Peterson, B. A., Tondini, C., Velasquez, W. A., and Yeap, B. Y. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med., 329: 987-994, 1993.
3. Lopez-Guillermo, A., Montserrat, E., Bosch, F., Terol, M. J., Campo, E., and Rozman, C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J. Clin. Oncol., 12: 1343-1348, 1994.
4. Hermans, J., Krol, A. D. G., van Groningen, K., Kluin, P. M., Kluin-Nelemans, J. C., Kramer, M. H. H., Noordijk, E. M., Ong, F., and Wijermans, P. W. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood, 86: 1460-1463, 1995.
5. Ansell, S. M., Habermann, T. M., Kurtin, P. J., Witzig, T. E., Chen, M. G., Li, C. Y., Inwards, D. J., and Colgan, J. P. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J. Clin. Oncol., 15: 2296-2301, 1997.
6. Bastion, Y., Blay, J. Y., Divine, M., Brice, P., Bordessoule, D., Sebban, C., Blanc, M., Tilly, T., Lederlin, P., Deconinck, E., Salles, B., Dumontet, C., Briere, J., and Coiffier, B. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival - a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J. Clin. Oncol., 15: 2945-2953, 1997.
7. Miller, T. P., Grogan, T. M., Dahlberg, S., Spier, C. M., Braziel, R. M., Banks, P. M., Foucar, K., Kjeldsberg, C. R., Levy, N., Nathwani, B. N., Schnitzer, B., Tubbs, R., Gaynor, E. R., and Fisher, R. I. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood, 83: 1460-1466, 1994.
8. Erlanson, M., Portin, C., Linderholm, B., Lindh, J., Roos, G., and Landberg, G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: prognostic implications. Blood, 92: 770-777, 1998.
9. Gascoyne, R. D., Krajewska, M., Krajewski, S., Connors, J. M., and Reed, J. C. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood. 90: 3173-3178, 1997.
10. Terol, M. J., Lopez-Guillermo, A., Bosch, F., Villamor, N., Cid, M. C., Rozman, C., Campo, E., and Montserrat, E. Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. J. Clin. Oncol., 16: 35-40, 1998.
11. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
12. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
13. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
14. Griffiths, S. D., Clarke, A. R., Healy, L. E., Ross, G., Ford, A. M., Hooper, M. L., Wyllie, A. H., and Greaves, M. Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene, 14: 523-531, 1997.
15. Ichikawa, A., Kinoshita, T., Watanabe, T., Kato, H., Nagai, H., Tsushita, K., Saito, H., and Hotta, T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med., 337: 529-534, 1997.
16. Midgley, C. A., and Lane, D. P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene, 15: 1179-1189, 1997.
17. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Nemcomb, E. W., Magrath, I. T., Knowles, D. M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88: 5413-5417, 1991.
18. Chilosi, M., Doglioni, C., Magalini, A., Inghirami, G., Krampera, M., Nadali, G., Rahal, D., Pedron, S., Benedetti, A., Scardoni, M., Macrì, E., Lestani, M., Menestrina, F., Pizzolo, G., and Scarpa, A. p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood, 88: 4012-4020, 1996.
19. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.
20. Koduru, P. R. K., Raju, K., Vadmal, V., Menezes, G., Shah, S., Susin, M., Kolitz, J., and Broome, J. D. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood, 90: 4078-4091, 1997.
21. Møller, M. B., Ino, Y., Gerdes, A-M., Skjødt, K., Louis, D. N., and Pedersen, N. T. Aberrations of the p53 pathway components p53, MDM2, and CDKN2A appear independent in diffuse large B-cell lymphoma. Leukemia, 13: 453-459, 1999.
22. Møller, M. B., d'Amore, F., and Christensen, B. E. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. Eur. J. Cancer, 30A: 1760-1764, 1994.
23. d'Amore, F., Brincker, H., Grønbæk, K., Thorling, K., Pedersen, M., Jensen, M. K., Andersen, E., Pedersen, N. T., and Mortensen, L. S. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. J. Clin. Oncol., 12: 1673-1684, 1994.
24. d'Amore, F., Johansen, P., Houmand, A., Weisenburger, D. D., and Mortensen, L. S. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood, 87: 1045-1055, 1996.
25. Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K., Cleary, M. L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K. C., Grogan, T. M., Isaacson, P. G., Knowles, D. M., Mason, D. Y., Müller-Hermelink, H. K., Pileri, S. A., Piris, M. A., Ralfkiær, E., and Warnke, R. A. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84: 1361-1392, 1994.
26. Hiddemann, W., Longo, D. L., Coiffier, B., Fisher, R. I., Cabanillas, F., Cavalli, F., Nadler, L. M., De Vita, V. T., Lister, T. A., and Armitage, J. O. Lymphoma classification - the gap between biology and clinical management is closing. Blood, 88: 4085-4089, 1996.
27. Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., Rosenberg, S. A., Coltman, C. A., and Tubiana, M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J. Clin. Oncol., 7: 1630-1636, 1989.
28. Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151: 237-244, 1992.
29. Altman, D. G. Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
30. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
31. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
32. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B, 34: 187-220, 1972.
33. Hernandez, L., Fest, T., Cazorla, M., Teruya-Feldstein, J., Bosch, F., Peinado, M. A., Piris, M. A., Montserrat, E., Cardesa, A., Jaffe, E. S., Campo, E., and Raffeld, M. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood, 87: 3351-3359, 1996.
34. Greiner, T. C., Moynihan, M. J., Chan, W. C., Lytle, D. M., Pedersen, A., Anderson, J. R., and Weisenburger, D. D. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood, 87: 4302-4310, 1996.
35. Wilson, W. H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S. M., Jaffe, E. S., and Raffeld, M. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood, 89: 601-609, 1997.
36. WAF1/CIP1, and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+ , MDM2-, p21-immunophenotype associated with missense p53 mutations. J. Pathol., 181: 51-61, 1997.
37. Detourmignies, L., Coppin, M. C., Morel, P., Vanrumbeke, M., Preudhomme, C., Wattel, E., Gaulard, P., Gisselbrecht, C., Gosselin, B., and Fenaux, P. p53 overexpression in diffuse large cell lymphoma (DLCL) and its prognostic value by multiparameter analysis (Abstract). Blood, 88: 383a, 1996.
38. WAF1/CIP1 immunoreactivity in non-Hodgkin's lymphomas predicts p53 gene status. Diagn. Mol. Pathol., 6: 222-228, 1997.
39. Nakamura, H., Said, J. W., Miller, C. W., and Koeffler, H. P. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood, 82: 920-926, 1993.
40. Villuendas, R., Piris, M. A., Algara, P., Sánchez-Beato, M., Sánchez-Verde, L., Martinez, J. C., Orradre, J. L., García, P., Lopez, C., and Martinez, P. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood, 82: 3151-3156, 1993.
41. Kocialkowski, S., Pezzella, F., Morrison, H., Jones, M., Laha, S., Harris, A. L., Mason, D. Y., and Gatter, K. C. Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br. J. Haematol., 89: 55-60, 1995.
42. WAF1/CIP1/SDI1 in differentiating human leukemic cells. J. Clin. Invest., 95: 973-979, 1995.
43. Friedlander, P., Haupt, Y., Prives, C., and Oren, M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol., 16: 4961-4971, 1996.
44. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
45. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
46. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S. J., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
47. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
48. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
49. Delia, D., Mizutani, S., Lamorte, G., Goi, K., Iwata, S., and Pierotti, M. A. p53 activity and chemotherapy. Nat. Med., 2: 724-725, 1996.
50. Fan, S., Cherney, B., Reinhold, W., Rucker, K., and O'Connor, P. M. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment. Clin. Cancer Res., 4: 1047-1054, 1998.